669 related articles for article (PubMed ID: 19678752)
1. Evidence for moxifloxacin in community-acquired pneumonia: the impact of pharmaco-economic considerations on guidelines.
Simoens S
Curr Med Res Opin; 2009 Oct; 25(10):2447-57. PubMed ID: 19678752
[TBL] [Abstract][Full Text] [Related]
2. A cost-effectiveness analysis of antimicrobial treatment of community-acquired pneumonia taking into account resistance in Belgium.
Martin M; Moore L; Quilici S; Decramer M; Simoens S
Curr Med Res Opin; 2008 Mar; 24(3):737-51. PubMed ID: 18230196
[TBL] [Abstract][Full Text] [Related]
3. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance.
Martin M; Quilici S; File T; Garau J; Kureishi A; Kubin M
J Antimicrob Chemother; 2007 May; 59(5):977-89. PubMed ID: 17395688
[TBL] [Abstract][Full Text] [Related]
5. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
6. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy.
Anzueto A; Niederman MS; Pearle J; Restrepo MI; Heyder A; Choudhri SH;
Clin Infect Dis; 2006 Jan; 42(1):73-81. PubMed ID: 16323095
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin monotherapy versus beta-lactam-based standard therapy for community-acquired pneumonia: a meta-analysis of randomised controlled trials.
An MM; Zou Z; Shen H; Gao PH; Cao YB; Jiang YY
Int J Antimicrob Agents; 2010 Jul; 36(1):58-65. PubMed ID: 20400271
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
[TBL] [Abstract][Full Text] [Related]
10. Community-acquired pneumonia in the elderly.
Fung HB; Monteagudo-Chu MO
Am J Geriatr Pharmacother; 2010 Feb; 8(1):47-62. PubMed ID: 20226392
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
Fogarty C; Torres A; Choudhri S; Haverstock D; Herrington J; Ambler J
Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolones in the management of community-acquired pneumonia in primary care.
Wispelwey B; Schafer KR
Expert Rev Anti Infect Ther; 2010 Nov; 8(11):1259-71. PubMed ID: 21073291
[TBL] [Abstract][Full Text] [Related]
13. Community acquired bacterial pneumonia.
Anevlavis S; Bouros D
Expert Opin Pharmacother; 2010 Feb; 11(3):361-74. PubMed ID: 20085502
[TBL] [Abstract][Full Text] [Related]
14. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
Segreti J; House HR; Siegel RE
Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
[TBL] [Abstract][Full Text] [Related]
15. Impact of guidelines on outcome: the evidence.
Martínez R; Reyes S; Lorenzo MJ; Menéndez R
Semin Respir Crit Care Med; 2009 Apr; 30(2):172-8. PubMed ID: 19296417
[TBL] [Abstract][Full Text] [Related]
16. Treatment of community-acquired pneumonia with moxifloxacin: a meta-analysis of randomized controlled trials.
Yuan X; Liang BB; Wang R; Liu YN; Sun CG; Cai Y; Yu XH; Bai N; Zhao TM; Cui JC; Chen LA
J Chemother; 2012 Oct; 24(5):257-67. PubMed ID: 23182045
[TBL] [Abstract][Full Text] [Related]
17. Role of moxifloxacin for the treatment of community-acquired [corrected] complicated intra-abdominal infections in Taiwan.
Lau YJ; Chen YH; Huang CT; Lee WS; Liu CY; Liu JW; Liu HD; Lee YJ; Chen CW; Ko WC; Hsueh PR
J Microbiol Immunol Infect; 2012 Feb; 45(1):1-6. PubMed ID: 22244019
[TBL] [Abstract][Full Text] [Related]
18. Community-acquired pneumonia: the U.S. perspective.
Niederman MS
Semin Respir Crit Care Med; 2009 Apr; 30(2):179-88. PubMed ID: 19296418
[TBL] [Abstract][Full Text] [Related]
19. [Updated acute community-acquired pneumonia in adults: Guidelines for initial antimicrobial therapy based on local evidence from the South American Working Group (ConsenSur II)].
Bantar C; Curcio D; Jasovich A; Bagnulo H; Arango A; Bavestrello L; Famiglietti A; García P; Lopardo G; Losanovscky M; Martínez E; Pedreira W; Piñeyro L; Remolif C; Rossi F; Varón F
Rev Chilena Infectol; 2010 Jun; 27 Suppl 1():S9-S38. PubMed ID: 20737129
[TBL] [Abstract][Full Text] [Related]
20. Economic impact of resistance in the community.
Eandi M; Zara GP
Int J Clin Pract Suppl; 1998 Jun; 95():27-38. PubMed ID: 9796553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
